This slide deck covers the treatment of triple-negative breast cancer, a heterogeneous disease made up of numerous subtypes, and includes clinical variables that can help with prognosis and guide in treatment choice.
Atezolizumab/Chemo Combo Yields Survival Benefit in Metastatic TNBC
December 21st 2023Lower risk of disease progression following treatment with atezolizumab and carboplatin for metastatic triple-negative breast cancer appears to be associated with increases in tumor infiltrating lymphocytes and tumor mutational burden.
Pembrolizumab Combo Does Not Improve PFS/OS in Advanced/Metastatic TNBC
December 7th 2023Data from the phase 2 KEYLYNK-009 study indicate a lower rate of treatment-related adverse effects with pembrolizumab plus olaparib compared with pembrolizumab plus chemotherapy in those with triple-negative breast cancer.